Frankfurt - Delayed Quote EUR

Denali Therapeutics Inc. (4DN.F)

12.77
+0.38
+(3.21%)
As of 8:17:56 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
330,531
108,463
48,661
Operating Expense
515,206
501,878
527,230
449,207
344,412
Operating Income
-515,206
-501,878
-196,699
-340,744
-295,751
Net Non Operating Interest Income Expense
61,333
64,636
51,505
14,774
4,595
Other Income Expense
--
14,537
--
--
--
Pretax Income
-453,873
-422,705
-145,194
-325,970
-291,156
Tax Provision
--
68
30
21
-575
Net Income Common Stockholders
-453,941
-422,773
-145,224
-325,991
-290,581
Diluted NI Available to Com Stockholders
-453,941
-422,773
-145,224
-325,991
-290,581
Basic EPS
-2.67
-2.57
-1.06
-2.60
-2.39
Diluted EPS
-2.67
-2.57
-1.06
-2.60
-2.39
Basic Average Shares
169,928.23
164,473.77
137,370.90
125,530.70
121,524.80
Diluted Average Shares
169,928.23
164,473.77
137,370.90
125,530.70
121,524.80
Total Operating Income as Reported
-515,206
-487,341
-196,699
-340,744
-295,751
Total Expenses
515,206
501,878
527,230
449,207
344,412
Net Income from Continuing & Discontinued Operation
-453,941
-422,773
-145,224
-325,991
-290,581
Normalized Income
-453,941
-437,310
-145,224
-325,991
-290,581
Interest Income
61,333
64,636
51,505
14,774
4,595
Net Interest Income
61,333
64,636
51,505
14,774
4,595
EBIT
-515,206
-501,878
-196,699
-340,744
-295,751
EBITDA
-505,164
-492,886
-179,973
-330,361
-287,158
Reconciled Depreciation
10,042
8,992
16,726
10,383
8,593
Net Income from Continuing Operation Net Minority Interest
-453,941
-422,773
-145,224
-325,991
-290,581
Total Unusual Items Excluding Goodwill
0
14,537
0
0
--
Total Unusual Items
0
14,537
0
0
--
Normalized EBITDA
-505,164
-507,423
-179,973
-330,361
-287,158
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 3/23/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARGX.VI argenx SE
512.60
+2.48%
 
BEAM Beam Therapeutics Inc.
18.58
+9.26%
 
AGEN Agenus Inc.
5.95
+15.31%
 
BNTX BioNTech SE
108.49
-1.51%
 
RXRX Recursion Pharmaceuticals, Inc.
5.49
+20.13%